Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates

Human Gene Therapy Methods

Volumn 23, Issue 5, 2012, Pages 285-296

  Reinboth, Jennifer ^a,b,c   Ascierto, Maria L ^b,d   Chen, Nanhai G ^a,e   Zhang, Qian ^a,e   Yu, Yong A ^a,e   Aguilar, Richard J ^a   Carretero, Rafael ^b,f   Worschech, Andrea ^c   Zhao, Yingdong ^b   Wang, Ena ^b   Marincola, Francesco M ^b   Szalay, Aladar A ^a,c,e,g  

^a GENELUX CORPORATION   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF GRANADA   (Spain)

^g UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MICROARRAY ANALYSIS; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS GENE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; WILD TYPE;

CELL LINE; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; GENE REGULATORY NETWORKS; HOST-PATHOGEN INTERACTIONS; HUMANS; ONCOLYTIC VIRUSES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 84878746275     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.057     Document Type: Article

References (60)

1. Ascierto, M.L., Worschech, A., Yu, Z., et al. (2011). Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer 11, 451.
2. Broyles, S.S., and Knutson, B.A. (2010). Poxvirus transcription. Future Virol. 5, 639-650.
3. Buller, R.M., and Palumbo, G.J. (1991). Poxvirus pathogenesis. Microbiol. Rev. 55, 80-122. (Pubitemid 21895147)
4. Buller, R.M., Smith, G.L., Cremer, K., et al. (1985). Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317, 813-815. (Pubitemid 16195408)
5. Chaudhury, A., Chander, P., and Howe, P.H. (2010). Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: Focus on hnRNP E1's multifunctional regulatory roles. RNA 16, 1449-1462.
6. Chen, N.G., Yu, Y.A., Zhang, Q., and Szalay, A.A. (2011). Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice. J. Transl. Med. 9, 164.
7. Cuezva, J.M., Krajewska, M., De Heredia, M.L., et al. (2002). The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 62, 6674-6681. (Pubitemid 35364137)
8. Dellis, S., Strickland, K.C., Mccrary, W.J., et al. (2004). Protein interactions among the vaccinia virus late transcription factors. Virology 329, 328-336. (Pubitemid 39423982)
9. Dreyfuss, G., Matunis, M.J., Pinol-Roma, S., and Burd, C.G. (1993). hnRNP proteins and the biogenesis of mRNA. Annu. Rev. Biochem. 62, 289-321. (Pubitemid 23237873)
10. Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95, 14863-14868. (Pubitemid 29003722)
11. Falkner, F.G., and Moss, B. (1990). Transient dominant selection of recombinant vaccinia viruses. J. Virol. 64, 3108-3111. (Pubitemid 20171312)
12. Flexner, C., Hugin, A., and Moss, B. (1987). Prevention of vaccinia virus infection in immunodeficient mice by vectordirected IL-2 expression. Nature 330, 259-262. (Pubitemid 18006420)
13. Frentzen, A., Yu, Y.A., Chen, N., et al. (2009). Anti-VEGF singlechain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 12915-12920.
14. Garber, K. (2006). China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98, 298-300.
15. Gentschev, I., Donat, U., Hofmann, E., et al. (2010). Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J. Biomed. Biotechnol. 2010, 489759.
16. Gentschev, I., Muller, M., Adelfinger, M., et al. (2011). Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 6, e22069.
17. Glass, W.G., Rosenberg, H.F., and Murphy, P.M. (2003). Chemokine regulation of inflammation during acute viral infection. Curr. Opin. Allergy Clin. Immunol. 3, 467-473. (Pubitemid 39149560)
18. Guang, S., Felthauser, A.M., and Mertz, J.E. (2005). Binding of hnRNP L to the pre-mRNA processing enhancer of the herpes simplex virus thymidine kinase gene enhances both polyadenylation and nucleocytoplasmic export of intronless mRNAs. Mol. Cell. Biol. 25, 6303-6313. (Pubitemid 41023208)
19. Guerra, S., Lopez-Fernandez, L.A., Pascual-Montano, A., et al. (2003). Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J. Virol. 77, 6493-6506. (Pubitemid 36588419)
20. Guo, Z.S., Parimi, V., O'Malley, M.E., et al. (2010). The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther. 17, 1465-1475.
21. Guo, Z.S., Thorne, S.H., And Bartlett, D.L. (2008). Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta. 1785, 217-231.
22. Hernandez-Alcoceba, R. (2011). Recent advances in oncolytic virus design. Clin. Transl. Oncol. 13, 229-239.
23. Hwang, B., Lim, J.H., Hahm, B., et al. (2009). hnRNP L is required for the translation mediated by HCV IRES. Biochem. Biophys. Res. Commun. 378, 584-588.
24. Izmailyan, R., and Chang, W. (2008). Vaccinia virus WR53.5/F14.5 protein is a new component of intracellular mature virus and is important for calcium-independent cell adhesion and vaccinia virus virulence in mice. J. Virol. 82, 10079-10087.
25. Jin, P., Zhao, Y., Ngalame, Y., et al. (2004). Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics 5, 55.
26. Katsafanas, G.C., and Moss, B. (2004). Vaccinia virus intermediate stage transcription is complemented by Ras-GTPaseactivating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer. J. Biol. Chem. 279, 52210-52217. (Pubitemid 39656595)
27. Kelly, K.J., Woo, Y., Brader, P., et al. (2008). Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum. Gene Ther. 19, 774-782.
28. Knutson, B.A., Liu, X., Oh, J., and Broyles, S.S. (2006). Vaccinia virus intermediate and late promoter elements are targeted by the TATA-binding protein. J. Virol. 80, 6784-6793. (Pubitemid 44025178)
29. Krecic, A.M., and Swanson, M.S. (1999). hnRNP complexes: composition, structure, and function. Curr. Opin. Cell Biol. 11, 363-371. (Pubitemid 29273808)
30. Lee, M.S., Roos, J.M., Mcguigan, L.C., et al. (1992). Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J. Virol. 66, 2617-2630.
31. Li, Z., and Nagy, P.D. (2011). Diverse roles of host RNA binding proteins in RNA virus replication. RNA Biol. 8, 305-315.
32. Lin, S.F., Yu, Z., Riedl, C., et al. (2007). Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 142, 976-983; discussion 976-983. (Pubitemid 350193250)
33. Liu, X., and Mertz, J.E. (1995). HnRNP L binds a cis-acting RNA sequence element that enables intron-dependent gene expression. Genes Dev. 9, 1766-1780.
34. McCart, J.A., Ward, J.M., Lee, J., et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61, 8751-8757. (Pubitemid 34013887)
35. Moss, B. (2007). Poxviridae: The Viruses and their Replication. (Lippincott Williams & Wilkins, Philadelphia).
36. Neumann, E., Riepl, B., Knedla, A., et al. (2010). Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts. Arthritis Res. Ther. 12, R83.
37. Pinol-Roma, S., and Dreyfuss, G. (1992). Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature 355, 730-732.
38. Prestwich, R.J., Errington, F., Diaz, R.M., et al. (2009). The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther. 20, 1119-1132.
39. Puhlmann, M., Brown, C.K., Gnant, M., et al. (2000). Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7, 66-73. (Pubitemid 30080989)
40. Sabatino, M., Zhao, Y., Voiculescu, S., et al. (2008). Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 68, 122-131. (Pubitemid 351380113)
41. Shida, H., Hinuma, Y., Hatanaka, M., et al. (1988). Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J. Virol. 62, 4474-4480. (Pubitemid 19006107)
42. Simon, R., Lam, A., Li, M.C., et al. (2007). Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 3, 11-17. (Pubitemid 47075796)
43. Smith, G.L., and Moss, B. (1983). Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 25, 21-28. (Pubitemid 14241202)
44. Tysome, J.R., Lemoine, N.R., and Wang, Y. (2009). Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes. Curr. Opin. Mol. Ther. 11, 664-669.
45. Van Vliet, K., Mohamed, M.R., Zhang, L., et al. (2009). Poxvirus proteomics and virus-host protein interactions. Microbiol. Mol. Biol. Rev. 73, 730-749.
46. Wang, E., Miller, L.D., Ohnmacht, G.A., et al. (2000). Highfidelity mRNA amplification for gene profiling. Nat. Biotechnol. 18, 457-459. (Pubitemid 30217539)
47. Wang, E., Voiculescu, S., Le Poole, I.C., et al. (2006). Clonal persistence and evolution during a decade of recurrent melanoma. J. Invest. Dermatol. 126, 1372-1377. (Pubitemid 43997921)
48. Weibel, S., Raab, V., Yu, Y.A., et al. (2011). Viral-mediated oncolysis is themost critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 11, 68.
49. Willers, I.M., and Cuezva, J.M. (2011). Post-transcriptional regulation of the mitochondrial H( + )-ATP synthase: a key regulator of the metabolic phenotype in cancer. Biochim. Biophys. Acta. 1807, 543-551.
50. Wong, H.H., Lemoine, N.R., and Wang, Y. (2010). Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2, 78-106.
51. Worschech, A., Kmieciak, M., Knutson, K.L., et al. (2008). Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res. 68, 2436-2446. (Pubitemid 351521819)
52. Worschech, A., Chen, N., Yu, Y.A., et al. (2009). Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 10, 301.
53. Wright, C.F., Oswald, B.W., and Dellis, S. (2001). Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins. J. Biol. Chem. 276, 40680-40686.
54. Yu, Y.A., Galanis, C., Woo, Y., et al. (2009a). Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol. Cancer Ther. 8, 141-151.
55. Yu, Z., Li, S., Brader, P., et al. (2009b). Oncolytic vaccinia therapy of squamous cell carcinoma. Mol. Cancer 8, 45.
56. Zaitseva, M., Vollenhoven, B.J., and Rogers, P.A. (2006). In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells. Mol. Hum. Reprod. 12, 187-207.
57. Zeh, H.J., and Bartlett, D.L. (2002). Development of a replicationselective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. 9, 1001-1012. (Pubitemid 35462562)
58. Zhang, Q., Yu, Y.A., Wang, E., et al. (2007). Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 67, 10038-10046. (Pubitemid 47621255)
59. Zhang, Q., Liang, C., Yu, Y.A., et al. (2009). The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol. Genet. Genomics 282, 417-435.
60. Zhu, M., Moore, T., and Broyles, S.S. (1998). A cellular protein binds vaccinia virus late promoters and activates transcription in vitro. J. Virol. 72, 3893-3899. (Pubitemid 28188690)